COVID is refuting the case for Medicare for All
HeraldNet | Sally C. Pipes
May 16, 2021
Low-income people have indeed suffered disproportionately amid the pandemic. It would seem intuitive that a guarantee of government health coverage would help them. But look at the outcomes posted by patients on Medicaid, the government health insurance program for the poor. Nationwide, Medicaid covers more than 70 million people.
|
|
The Biosimilar Opportunity: Quarterly Update No.3 – May 2021
PRI Center for Medical Economics and Innovation | Wayne Winegarden
May 17, 2021
In October 2019, the Center for Medical Economics and Innovation at the Pacific Research Institute released its second study documenting the savings potential enabled by biosimilars. Biosimilars are medicines manufactured in, or derived from, biological sources that are developed to be similar to FDA-approved reference products. Biosimilars are approved to compete in nine biologic drug classes in the U.S., and are available in seven of these drug classes currently.
Read more. . .
|
|
Insuring more Americans’ health shouldn’t require big government spending
Orlando Sentinel | Sally C. Pipes
May 17, 2021
These more generous subsidies are an extraordinarily expensive solution to a largely non-existent problem. About 28.9 million U.S. residents don’t have health insurance, according to new data from the Kaiser Family Foundation. That sounds like a lot.
Read more. . .
|
|
Private practices just became an endangered species
The Washington Examiner | Sally C. Pipes
May 14, 2021
But the bigger these provider groups get, the more leverage they have with insurance companies to insist on higher payment rates. Prices for physician services increase by nearly 15% after a practice is acquired by a hospital, according to a 2018 study in the Journal of Health Economics.
|
|
Sally Pipes Quoted About Price Transparency in Managed Healthcare Executive Magazine, "How the New Price Transparency Rules are Affecting Stakeholders"
Managed Healthcare Executive | Deborah Abrams Kaplan
May 13, 2021
Although the hospital price transparency final rule took effect in January, it will take time for it to get its sea legs, whether that means 100% hospital compliance, inspiring patients to use it for their own healthcare decisions or for hospitals to reevaluate their pricing based on their competition. Eventually, though, “I think it will open up the market and, hopefully, reduce the cost of healthcare,” says Sally Pipes, president of the Pacific Research Institute.
|
|
|
|
